Navigation Links
CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
Date:9/11/2007

KIRKLAND, Wash., Sept. 11 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the "Company") (OTC Bulletin Board: CCYG) has entered into a collaborative research agreement with physician scientists at the Cleveland Clinic Foundation of Cleveland, Ohio. The goal of the collaboration is to investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts, using CellCyte's proprietary compounds.

CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart. The goal of this therapy is to increase the number of stem cells delivered to a damaged organ, thereby increasing organ healing and functional restoration. The Company's first product in development, CCG-TH30, is designed to send autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack. In preclinical models, CCG-TH30 has been shown to increase the retention of stem cells up to as much as 80% compared to conventional methods, which achieve only up to about 7%. Importantly, CellCyte's product can be delivered intravenously through the patients' circulatory system without an invasive procedure.

The lead investigators of the project at Cleveland Clinic Foundation are Dr. Wilson Tang M.D. and Dr. Sathyamangla Prasad Ph.D., both accomplished and renowned scientists in the field of cardiac biology. Dr. Tang is also a physician and key opinion leader in cardiac medicine.

The Cleveland Clinic Foundation scientists will analyze heart tissue samples of heart failure patients for the presence of surface receptors that are hypothesized to play an important role in the interaction of stem cells with the heart. These studies are expected to provide valuable novel information that will increase the understanding of cardiac regeneration and will thereby sup
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Myriad Genetics Presents Tumor Origin Technology at AACR
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
10. Myriad Genetics Presents Azixas Mode of Action at AACR
11. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2008)...ladder Replacement Structurally Similar to, Native...ress Briefing and Post... May 19 /- Tengion,Inc., a clinical ...ment of,neo-organs and neo-vessels, presented prec...Replacement(TM) at the Annual Meeting of the Ameri...
(Date:5/19/2008)...swire/ -- Ikaria Holdings, Inc., a fully,integrate... today that it,has completed dosing of its Phase 1...lfide) for injection., The study was a Phase 1, r...e center dose escalation study of a single bolus i...s safety, tolerability and pharmacokinetics.,The s...
(Date:5/19/2008)...RNewswire/ -- IPSOGEN SA (Marseille and New,Haven)...cular diagnostic,assays for blood & breast cancers...sity of Texas MD Anderson Cancer Center (MDACC, Ho... on the Genomic Grade index (GGi) at the,ASCO Annu... 2008. The data,indicate that the Genomic Grade in...
(Date:5/18/2008)...ome fair coloring traits contribute to risk, of sk...CODEme(TM) service, REYKJAVIK, Iceland, May 18 /P...E scientists and academic colleagues from Europe a...ngs in the genetics of pigmentation,traits in peop...in of these,common variants also confer risk of tw...
Breaking Medicine Technology:Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection 2Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection 3Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 2Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 3Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 4deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 2deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 3deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 4NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7 2008 5112 1NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7 2008 5112 2Myanmar Cyclone 3A Women and Children Make up More than Half of Victims UNICEF 18473 1Myanmar Cyclone 3A Women and Children Make up More than Half of Victims UNICEF 18473 2West Coast Bank Sponsors Reach the Beach Cycling Fundraiser to Support the American Lung Association 18468 1West Coast Bank Sponsors Reach the Beach Cycling Fundraiser to Support the American Lung Association 18468 2Healthcare Realty Trust Announces First Quarter Results 18463 1Healthcare Realty Trust Announces First Quarter Results 18463 2Healthcare Realty Trust Announces First Quarter Results 18463 3Healthcare Realty Trust Announces First Quarter Results 18463 4Healthcare Realty Trust Announces First Quarter Results 18463 5Healthcare Realty Trust Announces First Quarter Results 18463 6Healthcare Realty Trust Announces First Quarter Results 18463 7Healthcare Realty Trust Announces First Quarter Results 18463 8
...May 14, 2007 - Acceleron Pharma,Inc., a biopharma...reatment of musculoskeletal, metabolic and cancer-...clinical study with,ACE-031 that demonstrated the ...d strength in normal mice and in murine models of,...lators of muscle,to increase muscle mass and stren...
...rket dynamics offers insights into,what will be ne...ients, NEW YORK, May 14, 2007 /PRNewswire-USNewsir...(TB Alliance), a not-for-profit,product developme...lopment of new TB drugs, today released results fr...f the global TB drug market,that offers a detailed...
Other Medicine Technology:Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4
(Date:5/20/2008)...sed skin health program, the first of its kind, ad...es affecting an increasingly diverse,America, airi...ay 24, 2008., SAN FRANCISCO, May 20 /PRNewswire/ ...esigned to educate and inform the public about the...omen,s Dermatologic Society (WDS),is pleased to an...
(Date:5/20/2008)... C is a health care problem all over the world, wi...he treatment is expensive and has variable results... The first land mark in treatment is the virus cle...tment Response (ETR), but many of the patients ach...months. Thus, the goal of treatment is to have per...
(Date:5/20/2008)...s to Aid America,s Wounded Warriors Facing Combat-... with Traumatic Brain Injury, WASHINGTON, May 20 ...elated vision loss have been among the most common...airmen and Marines serving in Iraq and,Afghanistan...er in,Washington, D.C., U.S. Rep. John Boozman, O....
(Date:5/20/2008)...ew England,s largest fertility clinics expands to ...e/ -- Reproductive Science Center,(RSC) of New Eng...kind,nationwide, announces a new partnership with ...ertility clinic at the hospital,s satellite facili... 250., Dr. Ania Kowalik, board-certified reproduc...
Breaking Medicine News(10 mins):Health News:Women's Dermatologic Society Announces Collaboration on 'America's Ethnic Skin: An Al Roker Health Special' 2Health News:Women's Dermatologic Society Announces Collaboration on 'America's Ethnic Skin: An Al Roker Health Special' 3Health News:Rep. Boozman, AOA Officials Tour Military Eye Care Facilities at Walter Reed Army Medical Center 2Health News:Rep. Boozman, AOA Officials Tour Military Eye Care Facilities at Walter Reed Army Medical Center 3Health News:Rep. Boozman, AOA Officials Tour Military Eye Care Facilities at Walter Reed Army Medical Center 4Health News:Reproductive Science Center and Lowell General Hospital Announce Partnership in Infertility Treatment 2
...mber of foreign-born health care workers in the Un...ansmitting tuberculosis in health-care settings.//...ts Timothy R. Sterling, M.D., and David W. Haas, M...ealth care workers with latent TB infection as ind...
...s who has a distinct edge joined the debate with m...'s brain suit inherently better for science than w... the similarities and differences among the gender...res' experience as a female-to-male transgendered ...
...ed by Australian researchers has discovered a new ...acid binding protein in human airway epithelial ce...ion. The researchers had explained in their stu... acid–binding protein aP2, which is known to regul...
...ts who consider suicide fail to seek help from a d...e who do ask for help may find it difficult to obt...to a new study. "We need to improve access to tre...n," said Ruth Klap, Ph.D., a sociologist at Univer...
Other Medicine News:Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 2Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 3Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 4Health News:Study Says - Blocking 'aP2' Protein Prevents Airway Diseases 2Health News:Many Suicidal Adults Aren't Getting Mental Health Treatment 2
...e beyond your investment., ,The Centiva/5 Critica...d time demands of the critical care environment. T... mind combining a compact size with high levels of...uable space around the patients bed and allows you...
...ther treatments for ,ED (e.g. Viagra, Injections...,Vacuum Therapy is gaining increasing ,popul...of the very positive associated benefits. ,In fa...ercise to prevent atrophy and to promote penile he...
...Mesh LP Self-Forming Plug is combining a lightweig... This results in a very soft hernia plug which sta...rd Plugs less foreign body material is included in... hernia size and shape allows for a softer and les...
...Mesh Self-Forming Plug is a mesh plug to treat lar...l hernias and femoralhernias. The self-expanding p...mpletely. Premilene Mesh Self-Forming Plug is a pr...h. The plug corresponds with all properties of Pre...
Medicine Products: